“I think it will be a very effective vaccine. That’s my prediction,” said Moncef Slavey, chief adviser to Operation Warp Speed. “My personal opinion is based on my experience and the biology of this virus, I think this vaccine will be very effective. I would not be surprised if it is 90% [range]. ”
Slavey, an immunologist, previously led the vaccine program at GlaxoSmithKline, where he led the development of five major new vaccines.
He said there would be enough vaccines for all Americans by mid-2021, but perhaps not by the end of 2021.
Slavey spoke Thursday with CNN senior medical correspondent Elizabeth Cohen during a tour of the Covid-19 clinical trial site in Savannah, Georgia. This was his first television interview since joining Operation Warp Speed in May.
When will there be a vaccine for everyone?
“The best thing we’ve ever done is measles, which is 97 to 98 percent effective,” said Foki, director of the National Institute of Allergy and Infectious Diseases. “It would be great if we got there. I don’t think we will. I would agree [a] 70, 75% effective vaccine “.
Vaccines have different efficacy rates. According to the US Centers for Disease Control and Prevention, the full cycle of polio vaccines is 99 to 100% effective; complete vaccination against diphtheria, tetanus and pertussis is 80-90% effective, and the effectiveness of influenza – 40-60%.
Slauy added that with the Kovid-19 vaccine, “we may need a booster” after the initial vaccination “every year or every two years or every three years.”
Slavey said he expects “likely to have tens of millions of doses” of the vaccine in December this year or January next year, and they will go to high-risk individuals because “we won’t have a dose for the entire U.S. population on the first day.”
People at high risk include the elderly and those with basic health conditions such as hypertension, diabetes and cardiovascular disease.
Slavey said he was “optimistic” that all Americans would have vaccines by the end of 2021, but ideally by mid-2021.
“This is our goal,” he said.
Vaccine trials are moving at a record pace
Operation Warp Speed is funding eight vaccines, Slavey said.
Five of them are already in phase 3 clinical trials or will begin by the end of September, he said. The Phase 3 trial is the last cycle of trials before the vaccine is available to regulators and can be marketed. Tests of the Covid-19 phase 3 vaccine will include 30,000 researchers.
“They’re all different vaccines. In fact, they go very fast,” Slaui said, noting that the virus was only identified six months ago. “I’ve been doing this for 30 years, and the fastest thing I ever remember is that it took four years from opening to three-phase testing.”
Modern and Pfizer vaccines are in phase 3 in the United States, and AstraZeneca is in phase 3 trials in the United Kingdom, Brazil and South Africa. Trials in this phase of Phase 3 are expected to begin in August in the United States.
Phase 3 vaccine trials by two other companies, Johnson & Johnson and Novavax, are set to begin in September, he added.
Slavey did not name the other three vaccines that will receive funding from Operation Warp Speed.
John Bonifield and Dana Vige made this report to CNN.